Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves Xeris Biopharma’s Recorlev in Cushing’s Syndrome | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

FDA Approves Xeris Biopharma’s Recorlev in Cushing’s Syndrome

Recorlev has the potential to fill key unmet needs for patients with uncontrolled CS.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Xeris Biopharma Holdings, Inc. received approval from the U.S. FDA for Recorlev (levoketoconazole) for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome for whom surgery is not an option or has not been curative.
 
Endogenous Cushing’s syndrome (CS) is a rare, serious and potentially lethal endocrine disease caused by chronic elevated cortisol exposure – often the result of a benign tumor of the pituitary gland. Nearly 40% of prescription-treated CS patients in the U.S. are not well-controlled, underscoring the need for new, safe and effective therapeutic options to help regulate cortisol levels.
 
Given the limited options, often with safety concerns or modest efficacy, Recorlev has the potential to fill key unmet needs for patients with uncontrolled CS in a market estimated to be $2 billion annually.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters